None
Quote | AbbVie Inc. (NYSE:ABBV)
Last: | $173.61 |
---|---|
Change Percent: | -0.58% |
Open: | $173.32 |
Close: | $173.61 |
High: | $174.7299 |
Low: | $172 |
Volume: | 4,037,366 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
News | AbbVie Inc. (NYSE:ABBV)
2024-07-21 21:02:13 ET More on health care stocks Elevance Health: Buy A Dividend Growth Machine Elevance extends losses as BofA cuts on Medicaid headwinds What Eli Lilly Is Getting With The Acquisition Of Morphic Holding Merck: Among The Best Health Ca...
2024-07-21 08:01:00 ET More on related stocks: Visa Earnings: A Good Quarter Could Still Mean A Muted Share Price Response Danaher Q2: Inventory Overhang, But Low Expectations Limit Downside Why Truist Financial Stock Is Not A Buy Ahead Of Q2 Earnings Ford st...
Message Board Posts | AbbVie Inc. (NYSE:ABBV)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $ABBV News Article - AbbVie Stock Plunged: Should You Buy the Dip? | whytestocks | investorshangout | 05/01/2023 7:35:47 PM |
$ABBV reports 1Q23 resultsraises non-GAAP EPS guidance: | DewDiligence | investorshub | 04/27/2023 12:00:28 PM |
$ABBVFDA expands Qulipta label_to prevention of chronic migraine: | DewDiligence | investorshub | 04/18/2023 6:23:32 PM |
Skyrizi phase-3 in UC hits all endpoints: | DewDiligence | investorshub | 03/23/2023 2:02:00 PM |
$ABBV advances Rinvoq to phase-3 in lupus: | DewDiligence | investorshub | 03/23/2023 2:00:38 PM |
News, Short Squeeze, Breakout and More Instantly...
2024-07-17 08:25:00 ET Stocks that are trading at low- and discounted-earnings multiples can sometimes be value traps. But other times, it's just due to short-term and temporary factors that the stocks aren't doing terribly well. In these situations, there are opportunities for investors to...
2024-07-14 04:27:00 ET The broader stock market benchmarks keep reaching new heights, but the S&P 500 index's ongoing bull run has been driven heavily by its largest components. That means there are still plenty of reliable dividend-paying stocks that look like bargains. Shares ...
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis PR Newswire Submissions are supported by the Phase 3 SELECT-GCA study demonstrating upadacitinib 15 mg with a 26-week steroid taper regimen achieved the primary endp...